FDA Will Not Maintain Advisory Assembly for MDD, PPD Drug Utility
Credit score: US Meals and Drug Administration The US Meals and Drug Administration (FDA) has introduced the company doesn’t plan on holding an advisory committee assembly for the New Drug Utility (NDA) for zuranolone, an investigational drug for the therapy of main depressive dysfunction (MDD) and postpartum melancholy (PPD). The therapy, developed by Biogen and […]
Continue Reading